Profile data is unavailable for this security.
About the company
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
- Revenue in USD (TTM)217.25m
- Net income in USD-50.92m
- Incorporated2012
- Employees173.00
- LocationProthena Corporation PLC77 Sir John Rogersons QuayBlock C, Grand Canal DocklandsDUBLIN D02 T804IrelandIRL
- Phone+353 12362500
- Fax+353 19023510
- Websitehttps://www.prothena.com/